UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis

Clinical infectious diseases, 2015-02, Vol.60 (4), p.549-556

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis

Antimicrobial agents and chemotherapy, 2015-10, Vol.59 (10), p.6073-6079

2015

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in the treatment of tuberculosis

Clinical microbiology and infection, 2023

2023

Link zum Volltext

Verfügbarkeit prüfen

Global tuberculosis drug development pipeline: the need and the reality

The Lancet (British edition), 2010-06, Vol.375 (9731), p.2100-2109

2010

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

The New England journal of medicine, 2014-10, Vol.371 (17), p.1599-1608

2014

Link zum Volltext

Verfügbarkeit prüfen

Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection

American journal of respiratory and critical care medicine, 2020-09, Vol.202 (6), p.866-877

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors

BMC infectious diseases, 2010-03, Vol.10 (1), p.83-83, Article 83

2010

Link zum Volltext

Verfügbarkeit prüfen

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Clinical infectious diseases, 2022-08, Vol.75 (1), p.141-151

2022

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus‐infected children in relation to treatment outcomes

British journal of clinical pharmacology, 2019-09, Vol.85 (9), p.2066-2075

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

PloS one, 2015-10, Vol.10 (10), p.e0141002

2015

Link zum Volltext

Verfügbarkeit prüfen

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis

Antimicrobial agents and chemotherapy, 2018-02, Vol.62 (2)

2018

Link zum Volltext

Verfügbarkeit prüfen

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens

Nature communications, 2021-05, Vol.12 (1), p.2899-2899, Article 2899

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

PLoS medicine, 2023-11, Vol.20 (11), p.e1004303-e1004303

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetics of plasma efavirenz exposure in HIV‐infected adults and children in South Africa

British journal of clinical pharmacology, 2015-07, Vol.80 (1), p.146-156

2015

Link zum Volltext

Verfügbarkeit prüfen

Treating children with tuberculosis—Using pharmacometrics to do better

British journal of clinical pharmacology, 2022-03, Vol.88 (3), p.894-896

McIlleron, Helen

2022

Link zum Volltext

Verfügbarkeit prüfen

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

International journal of infectious diseases, 2021-04, Vol.105, p.688-694

2021

Link zum Volltext

Verfügbarkeit prüfen

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial

Clinical infectious diseases, 2023-09, Vol.77 (6), p.875-882

2023

Link zum Volltext

Verfügbarkeit prüfen

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

The Journal of infectious diseases, 2013-11, Vol.208 (9), p.1464-1473

2013

Link zum Volltext

Verfügbarkeit prüfen

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype

AIDS (London), 2013-07, Vol.27 (12), p.1933-1940

2013

Link zum Volltext

Verfügbarkeit prüfen

Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.3232-3238

2012

Link zum Volltext

Verfügbarkeit prüfen

SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

Antimicrobial Agents and Chemotherapy, 2011-09, Vol.55 (9), p.4122-4127

2011

Link zum Volltext

Verfügbarkeit prüfen

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Link zum Volltext

Verfügbarkeit prüfen

Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients

Antimicrobial Agents and Chemotherapy, 2006-04, Vol.50 (4), p.1170-1177

2006

Link zum Volltext

Verfügbarkeit prüfen

Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients

Antimicrobial Agents and Chemotherapy, 2014-01, Vol.58 (1), p.503-510

2014

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

Journal of antimicrobial chemotherapy, 2014-05, Vol.69 (5), p.1339-1349

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(219)

Publikationsform

Artikel
(236)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(183)
Life Sciences & Biomedicine
(177)
Humans
(157)
Female
(113)
Infectious Diseases
(106)
Male
(103)
Pharmacology & Pharmacy
(94)
Tuberculosis
(90)
Microbiology
(87)
Adult
(78)
Hiv Infections - Drug Therapy
(70)
Human Immunodeficiency Virus
(60)
Hiv
(57)
Pharmacokinetics
(56)
Pharmacology
(55)
Tuberculosis - Drug Therapy
(55)
Antitubercular Agents - Therapeutic Use
(48)
Antitubercular Agents - Pharmacokinetics
(45)
Middle Aged
(45)
Biological And Medical Sciences
(44)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis

Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis

Recent advances in the treatment of tuberculosis

Global tuberculosis drug development pipeline: the need and the reality

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus‐infected children in relation to treatment outcomes

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

Pharmacogenetics of plasma efavirenz exposure in HIV‐infected adults and children in South Africa

Treating children with tuberculosis—Using pharmacometrics to do better

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype

Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines

SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine

Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients

Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

Suchergebnisse filtern